Skip to main content
Top
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk

Authors: Long Lv, Ping Wang, Xiaoqing Zhou, Beicheng Sun

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

Previous studies regarding the association of p53 codon 72 Arg/Pro polymorphism with hepatocellular carcinoma (HCC) risk have provided conflicting and inconclusive findings. Thus, a meta-analysis of all currently available publications was performed to address this issue. Eleven individual case–control studies involving a total of 2,718 cases and 3,752 controls were identified after a systematic search of the PubMed, Embase, Web of Science, and Wanfang databases. The strength of the association of p53 codon 72 Arg/Pro polymorphism with HCC risk was estimated by the pooled odds ratio (OR) with its corresponding 95 % confidence interval (95 % CI). Subgroup analyses stratified by ethnicity, source of controls, gender, hepatitis virus infection status, and family history of HCC were also conducted to assess the association. Overall, significantly increased risk of HCC was identified among carriers of the homozygous genotype ProPro (ORProPro vs. ArgArg = 1.38 (95 % CI, 1.03–1.85), P OR = 0.033; ORProPro vs. ArgArg + ArgPro = 1.28 (95 % CI, 1.03–1.59), P OR = 0.026). In subgroup analysis by ethnicity, the pooled results suggested that the p53 codon 72 Arg/Pro polymorphism was associated with an increased risk of HCC in Asians and Caucasians (for Asians, ORProPro vs. ArgArg + ArgPro = 1.17 (95 % CI, 1.02–1.34), P OR = 0.025; for Caucasians, ORProPro vs. ArgArg = 1.65 (95 % CI, 1.07–2.56), P OR = 0.025; ORProPro vs. ArgArg + ArgPro = 1.74 (95 % CI, 1.14–2.66), P OR = 0.010). Subgroup analyses by source of controls and hepatitis virus infection status further demonstrated the significant association, whereas stratification factors involving gender and family history of HCC did not modify the association between p53 codon 72 Arg/Pro polymorphism and HCC risk. This meta-analysis suggests that the p53 codon 72 Arg/Pro polymorphism may play a critical role in the development of HCC, and gender and family history of HCC may not modulate the effect of p53 codon 72 Arg/Pro in HCC risk.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
go back to reference Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev Anticancer Ther. 2001;1:277–90.PubMedCrossRef Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev Anticancer Ther. 2001;1:277–90.PubMedCrossRef
3.
go back to reference Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep. 2004;6:177–83.PubMedCrossRef Allen J, Venook A. Hepatocellular carcinoma: epidemic and treatment. Curr Oncol Rep. 2004;6:177–83.PubMedCrossRef
6.
7.
go back to reference Yam JW, Wong CM, Ng IO. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci (Schol Ed). 2010;2:117–34.CrossRef Yam JW, Wong CM, Ng IO. Molecular and functional genetics of hepatocellular carcinoma. Front Biosci (Schol Ed). 2010;2:117–34.CrossRef
8.
go back to reference Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993;262:1980–1.PubMedCrossRef Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993;262:1980–1.PubMedCrossRef
9.
go back to reference Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5:405–9.PubMed Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5:405–9.PubMed
10.
go back to reference Yamashita T, Yaginuma Y, Saitoh Y, Kawai K, Kurakane T, Hayashi H, et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis. 1999;20:1733–6.PubMedCrossRef Yamashita T, Yaginuma Y, Saitoh Y, Kawai K, Kurakane T, Hayashi H, et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis. 1999;20:1733–6.PubMedCrossRef
11.
go back to reference Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, et al. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol. 2012;33:927–33.PubMedCrossRef Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, et al. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol. 2012;33:927–33.PubMedCrossRef
12.
go back to reference Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008;29:2120–5.PubMedCrossRef Chen X, Sturgis EM, El-Naggar AK, Wei Q, Li G. Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. Carcinogenesis. 2008;29:2120–5.PubMedCrossRef
13.
go back to reference Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A. The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett. 2012;3:875–8.PubMed Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A. The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett. 2012;3:875–8.PubMed
14.
go back to reference Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481–6.PubMedCrossRef Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481–6.PubMedCrossRef
15.
go back to reference Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.PubMed
16.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
17.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
18.
19.
go back to reference Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70–1.PubMedCrossRef Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70–1.PubMedCrossRef
20.
go back to reference Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef
21.
go back to reference Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case–control study. Mol Biol Rep. 2012;39:1639–47.PubMedCrossRef Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case–control study. Mol Biol Rep. 2012;39:1639–47.PubMedCrossRef
22.
go back to reference Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6:13.PubMedCrossRef Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6:13.PubMedCrossRef
23.
go back to reference Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192–6.PubMedCrossRef Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192–6.PubMedCrossRef
24.
go back to reference Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37:748–54.PubMedCrossRef Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37:748–54.PubMedCrossRef
25.
go back to reference Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett. 2005;229:77–83.PubMedCrossRef Zhu ZZ, Cong WM, Liu SF, Xian ZH, Wu WQ, Wu MC, et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett. 2005;229:77–83.PubMedCrossRef
26.
go back to reference Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 2004;208:75–9.PubMedCrossRef Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 2004;208:75–9.PubMedCrossRef
27.
go back to reference Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193:199–205.PubMedCrossRef Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193:199–205.PubMedCrossRef
28.
go back to reference Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697–702.PubMedCrossRef Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697–702.PubMedCrossRef
29.
go back to reference Zhang YY, Yu HP, Fan XJ. Association of p53 codon72 polymorphism and risk of hepatocellular carcinoma. J Chin Oncol. 2012;18:189–93 [Article in Chinese]. Zhang YY, Yu HP, Fan XJ. Association of p53 codon72 polymorphism and risk of hepatocellular carcinoma. J Chin Oncol. 2012;18:189–93 [Article in Chinese].
30.
go back to reference Zhu ZZ, Cong WM, Zhu GS, Liu SF, Xian ZH, Wu WQ. Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22:632–5 [Article in Chinese].PubMed Zhu ZZ, Cong WM, Zhu GS, Liu SF, Xian ZH, Wu WQ. Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22:632–5 [Article in Chinese].PubMed
31.
go back to reference Peng T, Yan LN, Liu ZM, Shen HM, Ong CN, Peng MH, et al. Significant association of p53 codon 72 single neucletide polymorphism with hepatocellular carcinoma in Guangxi population. Chin J Surg. 2004;42:313–4 [Article in Chinese]. Peng T, Yan LN, Liu ZM, Shen HM, Ong CN, Peng MH, et al. Significant association of p53 codon 72 single neucletide polymorphism with hepatocellular carcinoma in Guangxi population. Chin J Surg. 2004;42:313–4 [Article in Chinese].
32.
33.
go back to reference Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int J Cancer. 2011;129:920–30.PubMedCrossRef Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int J Cancer. 2011;129:920–30.PubMedCrossRef
34.
go back to reference Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S. TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1840–7.PubMedCrossRef Dahabreh IJ, Linardou H, Bouzika P, Varvarigou V, Murray S. TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1840–7.PubMedCrossRef
35.
go back to reference Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.PubMedCrossRef Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.PubMedCrossRef
36.
go back to reference Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int. 2005;25:220–5.PubMedCrossRef Mahmood S, Niiyama G, Kamei A, Izumi A, Nakata K, Ikeda H, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int. 2005;25:220–5.PubMedCrossRef
37.
go back to reference Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26:153–61.PubMedCrossRef Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis. 2006;26:153–61.PubMedCrossRef
38.
go back to reference Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286:52–9.PubMedCrossRef Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 2009;286:52–9.PubMedCrossRef
Metadata
Title
Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk
Authors
Long Lv
Ping Wang
Xiaoqing Zhou
Beicheng Sun
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0649-7

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine